Verona Pharma Plc ADR [VRNA] stock is trading at $90.05, up 3.77%. An important factor to consider is whether the stock is rising or falling in short-term value. The VRNA shares have gain 7.23% over the last week, with a monthly amount glided 33.35%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Verona Pharma Plc ADR [NASDAQ: VRNA] stock has seen the most recent analyst activity on April 28, 2025, when TD Cowen initiated its Buy rating and assigned the stock a price target of $100. Previously, Cantor Fitzgerald started tracking the stock with Overweight rating on April 21, 2025, and set its price target to $80. On January 10, 2025, ROTH MKM initiated with a Buy rating and assigned a price target of $68 on the stock. Wells Fargo started tracking the stock assigning a Overweight rating and suggested a price target of $50 on October 03, 2024. In a note dated August 26, 2022, Piper Sandler initiated an Overweight rating and provided a target price of $31 on this stock.
Verona Pharma Plc ADR [VRNA] stock has fluctuated between $12.20 and $87.73 over the past year. Currently, Wall Street analysts expect the stock to reach $78 within the next 12 months. Verona Pharma Plc ADR [NASDAQ: VRNA] shares were valued at $90.05 at the most recent close of the market. An investor can expect a potential drop of -13.38% based on the average VRNA price forecast.
Analyzing the VRNA fundamentals
Gross Profit Margin for this corporation currently stands at 0.95% with Operating Profit Margin at -1.16%, Pretax Profit Margin comes in at -1.31%, and Net Profit Margin reading is -1.38%. To continue investigating profitability, this company’s Return on Assets is posted at -0.31, Equity is -0.9 and Total Capital is -0.29. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 87.44 points at the first support level, and at 84.83 for the second support level. However, for the 1st resistance point, the stock is sitting at 92.82, and for the 2nd resistance point, it is at 95.59.
Ratios To Look Out For
For context, Verona Pharma Plc ADR’s Current Ratio is 8.86. On the other hand, the Quick Ratio is 8.73, and the Cash Ratio is 7.1. Considering the valuation of this stock, the price to sales ratio is 64.66, the price to book ratio is 33.83.
Transactions by insiders
Recent insider trading involved DAVID ZACCARDELLI, Director, that happened on Jun 11 ’25 when 50000.0 shares were purchased. Officer, MARK HAHN completed a deal on Jun 11 ’25 to buy 50000.0 shares. Meanwhile, Chief Financial Officer Hahn Mark W sold 0.2 million shares on May 29 ’25.
